Literature DB >> 3074615

Evaluation of flunarizine in patients with Menière's disease. Subjective and vestibular findings.

T Haid1.   

Abstract

In an open multicentre pilot study, 32 patients affected with Menière's disease were treated with the cerebrally effective calcium antagonist flunarizine for 12 weeks. By means of the so-called vestibular index, the therapeutic results could be documented in a rapid and clear manner; the vestibular index takes into account both the subjective statements of the patients and objective pathological vestibular findings in terms of figures. The mean value of this vestibular index of 32 patients with Menière's disease was 9.5 before treatment and only 4.0 at the end of the therapy, which is indicative of a positive therapeutic effect. In the final evaluation, the action of flunarizine was generally considered very beneficial both by the attending physicians and the patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3074615

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  3 in total

1.  Procedures for restoring vestibular disorders.

Authors:  Leif Erik Walther
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

Review 2.  Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications.

Authors:  Giulio Di Mizio; Gianmarco Marcianò; Caterina Palleria; Lucia Muraca; Vincenzo Rania; Roberta Roberti; Giuseppe Spaziano; Amalia Piscopo; Valeria Ciconte; Nunzio Di Nunno; Massimiliano Esposito; Pasquale Viola; Davide Pisani; Giovambattista De Sarro; Milena Raffi; Alessandro Piras; Giuseppe Chiarella; Luca Gallelli
Journal:  Int J Environ Res Public Health       Date:  2021-12-08       Impact factor: 3.390

3.  Optimizing the pharmacological component of integrated balance therapy.

Authors:  Maurício Malavasi Ganança; Heloisa Helena Caovilla; Mário Sérgio Lei Munhoz; Cristina Freitas Ganança; Maria Leonor Garcia da Silva; Flavio Serafini; Fernando Freitas Ganança
Journal:  Braz J Otorhinolaryngol       Date:  2007 Jan-Feb
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.